Despite the advancements in modern medicine, treatment-resistant depression remains a global challenge. For patients who have spent years searching for a solution in vain, the scientific community is increasingly considering innovative, psychedelic-based interventions.
Over the last decade, the scientific world has witnessed a so-called “Psychedelic Renaissance.” This is a period where substances that were taboo for decades have returned to leading laboratories and clinical trials—this time accompanied by strict medical oversight and cutting-edge technology. Beyond temporary symptom relief, this approach aims for fundamental changes in functional brain dynamics and the restoration of neuroplasticity.
In this article, Davit Sagharadze, the only internationally certified psychedelic therapist in Georgia, shares his 35 years of clinical experience and the knowledge he gained in Canada. Sagharadze explains in detail the principles of Ketamine-Assisted Psychotherapy (KAP), the neurobiological mechanisms of the drug’s action, and the unique opportunities this approach creates in managing treatment-resistant depression.
Mr. Davit, what is Treatment-Resistant Depression?
Treatment-Resistant Depression (TRD) is a condition where a patient does not respond to at least two different antidepressant treatments administered at an adequate dose and duration. Often, this means years of various therapeutic attempts, frustration, and a significant decline in functioning. In such cases, the need for alternative approaches arises.
What does “Psychedelic Therapy” mean?
Psychedelic substances have been used for millennia in ritual and healing practices. Modern research studies how certain substances can temporarily increase neuroplasticity and facilitate the psychotherapeutic process. Classic psychedelics (LSD, DMT, Ibogaine, Mescaline) are mostly in various stages of research and are not yet widely used in clinical practice. However, the use of Psilocybin and MDMA for treating depression and PTSD is very close to FDA approval.
What is the legal alternative today?
Currently, one of the legally available approaches for treatment-resistant depression is Ketamine-Assisted Therapy (KAP). Ketamine is not a classic psychedelic. It acts on the glutamate system and can rapidly reduce depressive symptoms.
How does clinical ketamine therapy differ from non-medical, recreational use, and why is self-medication dangerous?
The difference is fundamental. Recreational use is associated with serious risks:
-
Psychological Risks: Panic reactions, delirium, prolonged depersonalization (the so-called “K-hole”), and the provocation of psychosis.
-
Physical Dangers: “Street ketamine” is not pure and often contains fentanyl or benzodiazepines, posing a risk of respiratory depression.
-
Organ Damage: Long-term use in high doses causes irreversible damage to the bladder walls.
-
Cognitive Decline: Impairment of memory and executive functions during chronic use. In a clinical setting, only chemically pure pharmaceutical-grade products are used, with precise dosing and constant medical supervision.
How do interventions like DMT or Ketamine manage to change brain patterns that standard antidepressants couldn’t tackle?
Clinical trials have shown that a single 25-minute DMT session resulted in sustained improvement for six months in patients with TRD. In cases of TRD or OCD, the brain is often “locked” in repetitive negative patterns—particularly in self-referential and ruminative networks. Standard antidepressants soothe this system slowly but fail to change its structural organization.
When using DMT, Psilocybin, or Ketamine, these pathological patterns are temporarily disrupted at the cellular level, opening a “window of opportunity.” Synaptic flexibility increases, and the brain finds it easier to form new, healthy connections. These drugs don’t just “increase serotonin”—they temporarily shift the brain’s functional dynamics, giving it a chance to exit a pathological mode that has been reinforced over years.
How high is the risk of addiction to psychedelic substances during therapeutic use?
Under professional supervision, this risk is practically non-existent. In a therapeutic regimen, Ketamine is not used daily—the minimum interval between sessions is 72 hours (averaging two ketamine sessions and one integration session per week). Furthermore, a strict medical evaluation is conducted beforehand, and blood pressure, pulse, and respiration are constantly monitored during the session in the presence of an anesthesiologist and a therapist.
What is the difference between Ketamine and antidepressants in terms of efficacy?
KAP is characterized by a faster clinical response: a reduction in symptoms is observed in 70–85% of cases within 24–72 hours (compared to 50–65% for antidepressants). The sustained remission rate (≥3 months) for KAP is 50–70%, whereas, with the standard approach, it ranges between 30–40%. Importantly, without psychotherapeutic integration, the long-term effect of ketamine is significantly lower (20–30%).
How does Ketamine work on a neurobiological level?
Ketamine reduces pathological hyperactivity in certain brain regions and promotes synaptogenesis—the formation of new neuronal connections. This process results in a “window of opportunity” (24–48 hours) when the brain is more plastic and open to new patterns of thinking. Ketamine creates the biological conditions that enhance the impact of psychotherapeutic work.
On a subjective level, what does the patient feel during the session?
A session lasts 45–60 minutes. The patient may experience altered perception, visual imagery, emotional release, dissociation, or a feeling of weightlessness. The process takes place in a calm environment, with an eye mask, specialized music in headphones, and the constant presence of a therapist, ensuring safety and emotional comfort.
For which conditions is it used?
Ketamine-Assisted Therapy is used for treatment-resistant depression, severe depressive episodes, the need for rapid reduction of suicidal ideation, as well as PTSD, anxiety disorders, addictions, and cognitive-emotional disorders.
How does KAP work in practice?
The process is based on three stages: Preparation – Session – Integration. During preparation, a psychiatric evaluation is conducted. The session is held under medical supervision. The integration stage is critical, as this is when the “window” opened by the ketamine is used to consolidate new experiences.
What are the main contraindications?
Therapy is not recommended for psychotic disorders, the manic phase of bipolar disorder, uncontrolled hypertension, severe cardiovascular pathologies, active substance abuse, and pregnancy.
What is the outlook in Georgia?
Awareness in Georgia is still low. International experience dictates that such approaches should only develop within an evidence-based, regulated, and ethically protected framework, with strict adherence to professional standards.
